Hematologic Malignancy
Primary Cutaneous Anaplastic Large Cell Lymphoma
CI-CAN-00003732C-ALCLExplore in graph →
Hematologic3 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003732C-ALCLExplore in graph →
Clinical trials
8 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)(ALCANZA) | completed | Phase 3 | 131 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Jan 5, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jan 5, 2021source: clinicaltrials